drugset / Trial / NCT00161421

Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone

NCT00161421

Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to test the how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future. We will be administering three drugs. Dutasteride is FDA approved to treat prostate enlargement. Lupron is approved for treatment of prostate cancer. Testosterone is approved for treatment of testicular insufficiency. They are being used in this study for "off-label" research purposes. This study will allow us to find out the effect of food on two formulations of testosterone taken by mouth, and the relative effect of food on testosterone absorption. Information from this study may be useful in treatment of men with low testosterone levels and the development of a male hormonal contraceptive.

Timeline

Start
2005-03
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 200 mg Oral
Subject Testosterone Small molecule 400 mg Oral
Background Dutasteride Small molecule 0.5 mg
Background Leuprolide Other / unclassified 7.5 mg Intramuscular

Indications